The unaffected BrdU+/NeuN+ cell count in the 10 mg/kg HE group suggests the involvement of other cell types mediating the therapeutic effects of HE, such as neural stem cells or glial cells. The gene discussed is RBFOX3; the disease is hereditary elliptocytosis.